BICO News Feed
Stefan Blomsterberg appointed as new CEO of CELLINK Bioprinting AB
CELLINK Bioprinting AB (CELLINK) has announced a change of leadership with
Stefan Blomsterberg taking over as CEO from Cecilia Edebo who will be pursuing another opportunity.
Stefan Blomsterberg has been appointed as the new CEO of CELLINK. Cecilia Edebo, current CEO, requested earlier this year to resign from her position to pursue a new career opportunity outside the BICO Group. At the time of her resignation, a recruitment process was initiated which concluded in the appointment of Stefan Blomsterberg.
Stefan Blomsterberg (born 1964) brings 20+ years of experience from the medtech industry, having held leadership positions at Vitrolife, Mölnlycke Healthcare and most recently as CEO of Medfield Diagnostics AB. Stefan has broad experience in global business development and is well versed in launching innovative high-tech life science products on the market, while fostering a sustainable business strategy.
During Cecilia Edebo’s tenure as CEO of CELLINK she, together with her team, heightened focus on building a long-term sustainable business. This involved driving profitability, while continuing growth through innovative research and development. In her three years, CELLINK successfully launched multiple bioprinting systems, resulting in an expanded light-based portfolio and solutions targeting the pharmaceutical industry. Under her leadership CELLINK continued to be a driving force in fostering collaboration in the bioprinting space by opening Centres of Excellence at leading institutions in the USA, India, and Singapore as well as establishing strategic partnerships with other commercial organizations to further advance bioprinting.
A transition plan will now be implemented for a seamless transfer of responsibility between Cecilia Edebo and Stefan Blomsterberg that ensures continued operational efficiency.
For further information, please contact:
Avi Minocha, Head of Marketing CELLINK
Phone: +1 (617) 637-5372
CELLINK is enabling the future of health as part of BICO, the world’s leading bioconvergence company. When CELLINK released the first universal bioink in 2016, it democratized the cost of entry for researchers around the world and played a major role in turning the then up-and-coming field of 3D bioprinting into a thriving $1 billion industry. Today, the company’s best-in-class bioinks, bioprinters, software and services have been cited in over 1000 publications and are trusted by more than 1,600 academic, pharmaceutical and industrial labs. With a comprehensive portfolio of world-class 3D bioprinters and bioinks CELLINK’s technology enables the printing of human tissues and organs, which enable faster and more accurate models for drug development, while replacing animal experiments and paving the way to save lives by reducing organ rejection and potentially solve the problem with lack of donors. 2022 CELLINK made a strategic investment to reach our business mission and continue to push the boundaries of how 3D bioprinting can contribute to the future of health. Visit www.cellink.com to learn more. BICO is listed on the Nasdaq Stockholm Main Market under BICO.